by GOAI

由GOAI生成

Share To

分享到

Eli Lilly has introduced a new approach to early-stage innovation through its biotech collaboration model, according to Thomas Hopkins, Vice President and Head of ExploR&D at the company. The strategy focuses on fostering partnerships with biotechnology firms to accelerate drug discovery and development.

据该公司ExploR&D副总裁兼负责人托马斯·霍普金斯称，礼来公司通过其生物技术合作模式推出了一种早期创新的新方法。该战略侧重于与生物技术公司建立合作伙伴关系，以加速药物的发现和开发。

This collaborative framework aims to leverage external expertise and resources while integrating them with Eli Lilly’s internal capabilities..

该合作框架旨在利用外部专业知识和资源，同时将其与礼来公司的内部能力相结合。

Hopkins discussed the initiative in detail, highlighting how it seeks to address challenges in early-stage research by combining the strengths of smaller biotech companies with Eli Lilly’s infrastructure and experience. The model emphasizes shared risk and reward, aiming to streamline the process of bringing innovative therapies to market.

霍普金斯详细讨论了这一倡议，强调了它如何通过结合小型生物技术公司的优势与礼来公司的基础设施和经验，来应对早期研究中的挑战。该模式强调风险与回报共享，旨在简化将创新疗法推向市场的过程。

By working closely with external partners, Eli Lilly intends to enhance efficiency in identifying promising drug candidates and advancing them through clinical trials..

通过与外部合作伙伴密切合作，礼来公司打算提高识别有希望的候选药物的效率，并推动它们通过临床试验。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈，请联系我们。

Date: February 6, 2026

日期：2026年2月6日

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 保留所有权利。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章